Park YH - Search Results

1

Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.

Iwata H, Xu B, Kim SB, Chung WP, Park YH, Kim MH, Tseng LM, Chung CF, Huang CS, Kim JH, Chiu JWY, Yamashita T, Li W, Egorov A, Nishijima S, Nakatani S, Nishiyama Y, Sugihara M, Cortés J, Im SA. Iwata H, et al. Among authors: park yh. Cancer Sci. 2024 Sep;115(9):3079-3088. doi: 10.1111/cas.16234. Epub 2024 Jul 9. Cancer Sci. 2024. PMID: 38979893 Free PMC article. Clinical Trial.

2

Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.

Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS. Im SA, et al. Among authors: park yh, park hs. Oncol Rep. 2005 Aug;14(2):481-7. Oncol Rep. 2005. PMID: 16012734 Clinical Trial.

3

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J. Lee KS, et al. Among authors: park yh. Breast Cancer Res Treat. 2008 Mar;108(2):241-50. doi: 10.1007/s10549-007-9591-y. Epub 2007 May 3. Breast Cancer Res Treat. 2008. PMID: 17476588 Clinical Trial.

4

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.

Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH. Uhm JE, et al. Among authors: park yh, park mj, park k. Int J Cancer. 2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090. Int J Cancer. 2009. PMID: 19065658

5

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.

Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ. Kim ST, et al. Among authors: park yh, park k. Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130. Cancer. 2010. PMID: 20564408 Free article.

6

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ. Chang MH, et al. Among authors: park yh, park k. Cancer. 2011 Jan 1;117(1):143-51. doi: 10.1002/cncr.25560. Epub 2010 Aug 27. Cancer. 2011. PMID: 20803614 Free article.

7

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.

Yi SY, Ahn JS, Uhm JE, Lim DH, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH. Yi SY, et al. Among authors: park yh, park mj. BMC Cancer. 2010 Oct 5;10:527. doi: 10.1186/1471-2407-10-527. BMC Cancer. 2010. PMID: 20920367 Free PMC article.

8

Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

Lee SJ, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH. Lee SJ, et al. Among authors: park yh. Cancer Chemother Pharmacol. 2011 Sep;68(3):743-51. doi: 10.1007/s00280-010-1545-0. Epub 2010 Dec 18. Cancer Chemother Pharmacol. 2011. PMID: 21170649

9

Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer.

Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Lee SJ, et al. Among authors: park yh, park s. Cancer Res Treat. 2011 Jun;43(2):89-95. doi: 10.4143/crt.2011.43.2.89. Epub 2011 Jun 30. Cancer Res Treat. 2011. PMID: 21811424 Free PMC article.

10

Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: is there a subpopulation that might have benefit from adjuvant chemotherapy?

Park YH, Im SA, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. Park YH, et al. Breast Cancer Res Treat. 2012 May;133(1):247-55. doi: 10.1007/s10549-012-1956-1. Epub 2012 Jan 21. Breast Cancer Res Treat. 2012. PMID: 22270935

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,117 results

Search Page

Filters